July 9, 2019
Glenmark OKd by USFDA for generic of Ranexa
Glenmark Pharmaceuticals got the final approval by the US FDA for its Ranolazine Extended-Release Tablets, generic version of Gilead’s Ranexa.
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
July 9, 2019
Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way
“The SWIFF-CAR system does precisely that, representing a major breakthrough in our ongoing efforts to develop innovative applications to treat a range of diseases, including cancer and autoimmune diseases.”
July 8, 2019
ObsEva wraps up patients recruitiment for testing linzagolix, to treat certain heavy menstrual bleeding
ObsEva has completed recruiting patients for its Phase 3 clinical trial PRIMROSE 1 testing of oral gonadotropin releasing hormone (GnRH) receptor antagonist linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids (UF).
July 8, 2019
Lannett to distribute Levothyroxine Sodium tablets in USA
Lannett Company has entered into a future exclusive supply and distribution agreement for the approved Levothyroxine Sodium Tablets USP of Cediprof, Inc., a wholly owned subsidiary of privately held Neolpharma Pharmaceutical Group.
July 8, 2019
Launching of Lung Ambition Alliance aims to double five-year survival in lung cancer in 6 years
Astrazeneca has entered partnership with the International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (GLCC) named the Lung Ambition Alliance, to try to eliminate lung cancer as a cause of death.
July 5, 2019
FDA approves Karyopharm’s treatment for refractory multiple myeloma
The U.S. FDA has granted accelerated approval to Karyopharm Therapeutics’s Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of certain adult patients with relapsed refractory multiple myeloma (RRMM).
July 3, 2019
ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
– ULTOMIRIS has the potential to become the new standard of care for both complement inhibitor-naïve patients and patients switching from SOLIRIS® (eculizumab) –
July 3, 2019
Dr. Reddy’s Laboratories Announces First-to-market Launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial in the U.S. Market
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial, a therapeutic equivalent generic version of Hemabate® injection, 250 mcg/mL, approved by the U.S. Food and Drug Administration (USFDA).
July 2, 2019
EnPro Industries Announces Acquisition of The Aseptic Group
EnPro Industries, Inc. (NYSE: NPO), a leading manufacturer of engineered industrial products, today announced it has acquired The Aseptic Group (comprising Aseptic Process Equipment SAS and Aseptic Services SARL), a privately-held company which distributes, designs and manufactures aseptic fluid transfer products for the pharmaceutical and biopharmaceutical industries.
July 2, 2019
Novocure to Report Second Quarter 2019 Financial Results
Novocure announced today that it will report financial results for the second quarter 2019 on Thursday, July 25, 2019, before the U.S. financial markets open.